anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses an external applying Chinese medicine used for treating the disease of each section of the cervical vertebra, the lumbar vertebra and the external injury vertebra, which uses safflowers, frankincense, drynaria, myrrh, large-leaf gentian roots, earthworms, native copper, radix aconiti, borneol, etc., as raw materials. The raw materials are triturated in compatibility according to the different characteristics of each traditional Chinese medicine. The native copper is pulverized in 160 meshes, the borneol is not required to be pulverized, and the other traditional Chinese medicines are mixed and pulverized into the medical powder of 120 meshes. Then the pulverized native copper is mixed with the other traditional Chinese medicinal powder except the borneol. After the mix, the clear water is added, the weight proportion of the total medicine quantity and the clear water is 1: 6.6. The medicine and the water are boiled for 15 minutes and are agitated in the boiling process. After the fire is stopped, the agent is in a paste form, and the weight part of the borneol is added when the agent is cooled to the temperature about 40 DEG C for mixed agitation. Then the agent is spread out on cotton cloth according to the weight of 28.8 g per part to be attached on a sick part. The external applying Chinese medicine is changed per 25 hours, 10 times are a treating course, the curing rate is 95%, and the effective rate is 98%. The present invention has the advantages of low cost, simple preparation, convenient use and easy popularization and application.
AVERT is a multicenter, Phase II clinical trial comparing a novel diagnostic strategy (VRT) to standard ED diagnostic care at three performance sites. The Specific Aims are to assess diagnostic accuracy, diagnostic workup costs, and estimate the short-term impact of correct diagnosis in anticipation of a larger, definitive Phase III trial. Adult ED patients with a chief symptom of vertigo, dizziness, or unsteadiness, new or clearly worse in the previous 30 days, will undergo on-site vestibular function tests by trained research personnel using a portable, quantitative VOG recording device. Research personnel will also record a focused symptom history and bedside hearing tests. Eligible patients with at least one pathologic vestibular eye movement finding or pathologic ataxia will be randomized to VRT or standard ED care. Patients eligible for pre-randomization testing but excluded from randomization will be slated for the Observational Arm of the study and will undergo limited 1 and 6 month phone follow-up. The VRT arm relies on an automated algorithm to interpret VOG results, thereby determining a patient-specific clinical care pathway. For safety, all VRT-arm study subjects will undergo stroke protocol MRI before release. All randomized subjects will undergo confirmatory testing at one week, including vestibular specialist exam and 1.5 or 3-Tesla research MRI combining stroke and internal auditory canal protocols. All randomized patients will also undergo 1 month and 6 month phone follow-up and medical record review to confirm diagnoses. Clinical findings, ED diagnoses, diagnostic resource utilization, treatments applied, and clinical events during follow-up will be recorded. A multidisciplinary, masked, expert panel will adjudicate final diagnoses.
Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
Azithromycin for oral suspension can be taken with or without food.

The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.

Pharyngitis/Tonsillitis: The recommended dose of azithromycin for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)

Constituting instructions for azithromycin Oral Suspension 300, 600, 900, 1200 mg bottles. The table below indicates the volume of water to be used for constitution:

Shake well before each use. Oversized bottle provides shake space. Keep tightly closed.

After mixing, store suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.
The invention provides a use of a compound capable of at least in part influencing an activity of a neural reflex pathway for the preparation of a medicament for altering the motility of the gastrointestinal tract. Said medicament can be used for prophylaxis and/or treatment of hypomotility of the gastrointestinal tract. Preferably, generalized hypomotility occurring during postoperative ileus is prevented and/or treated by a medicament of the invention.In one aspect of the invention said activity of said neural reflex pathway is decreased by at least in part preventing stimulation of said pathway by an immunocyte, a macrophage and/or a mast cell. Said activity can also be decreased by at least in part preventing immunocyte recruitment. A compound capable of at least in part influencing an activity of a neural reflex pathway for instance comprises an anti-ICAM-1 antibody, an anti LFA-1 antibody, and/or ketotifen. A pharmaceutical composition for prophylactic and/or therapeutic treatment of an individual against hypomotility of the gastro-intestinal tract comprising a compound capable of at least in part decreasing a neural reflex pathway is also herewith provided.
PURPOSE:To obtain an emulsifying agent which is excellent in emulsifying power and less sticky and gives a rich feeling and a good skin permeation by using collagen peptide potassium of coconut oil fatty acid and liq. oil in combination with a higher alcohol. CONSTITUTION:The subject emulsifying composition contains liq. oil such as collagen peptide potassium of coconut oil fatty acid, avocado oil and liq. paraf fin and higher alcohol such as behenyl alcohol and batyl alcohol. This emulsify ing composition is excellent in emulsifying power and less sticky and the system using this emulsifying composition gives a rich feeling and a good skin permea tion.
PURPOSE:To measure low molecular and high molecular antigens with good sensitivity by bringing an antigen and an enzyme labeled antibody into reaction then conjugating the unreacted enzyme labeled antibody with a column packed therein with an antigen insolubizing carrier. CONSTITUTION:A standard insulin liquid and a soln. of an enzyme labeled antibody are first mixed and are brought into reaction with each other for about 2hr at about 37 deg.C. The reaction liquid is passed to an antigen column used for prepn. of the insulin insolubilizing cephalose obtd. by bringing insulin and the cephtlose activated by cyan bromide into reaction with each other to wash the column and thereafter the column is filled with a soln. of O-nitrophenyl-beta-D-galactoside which is the substrate of beta-D-galactosidase and an enzyme reaction is effected overnight at a room temp. (25 deg.C). The column is then washed with a sodium carbonate soln. and the quantity of the O-nitrophenol in the resulted washing liquid is photometrically measured.
STUDY OBJECTIVES: Postoperative respiratory adverse events (PRAE) occurred more frequently in children having adenotonsillectomy than the general surgical population, and can require escalation of care. This study aims to assess the usefulness of postinduction fentanyl-test to predict PRAE in children with obstructive sleep apnea after adenotonsillectomy.
METHODS: Two hundred and forty patients with obstructive sleep apnea undergoing adenotonsillectomy were included in this study. The oxygen saturation during sleep was monitored the night before adenotonsillectomy. Fentanyl-test was conducted under spontaneous breath after anesthesia induction with sevoflurane. Fentanyl-induced reduction in respiratory rate (FRR) was defined as the percentage of reduction in respiratory rate after 1 mcg/kg fentanyl administration. PRAE in the postanesthesia care unit included both respiratory complications and medical interventions. Receiver operating characteristic analysis was used to assess the usefulness of fentanyl-test in predicting PRAE.
RESULTS: Of the 240 children undergoing elective adenotonsillectomy, 38 children (16%) experienced PRAE in postanesthesia care unit. The areas under receiver operating characteristic curve for FRR and nadir pulse oxygen saturation were 0.756 and 0.692, respectively. FRR greater than 53% best predicted PRAE in postanesthesia care unit, with a sensitivity of 68% and a specificity of 72%. Patients with FRR > 53% exhibited a significantly longer duration of desaturation requiring supplementary oxygen than those with FRR ≦ 53% (P < .001).
CONCLUSIONS: We suggest that postinduction fentanyl-test is a feasible evaluation for children undergoing adenotonsillectomy to predict early PRAE, especially for those who have not undergone polysomnography.
CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Effects of Individualized Opioid Analgesia Versus Conventional Opioid Analgesia After Adenotonsillectomy in Children; URL: https://clinicaltrials.gov/study/NCT04527393; Identifier: NCT04527393.
CITATION: Liu H-E, He L. The performance of a post-induction fentanyl-test in predicting postoperative respiratory adverse events in children after adenotonsillectomy. J Clin Sleep Med. 2024;20(11):1749-1754.
Inherited cardiac arrhythmias are a group of genetic diseases predisposing to sudden cardiac arrest, mainly resulting from variants in genes encoding cardiac ion channels or proteins involved in their regulation. Currently available therapeutic options (pharmacotherapy, ablative therapy and device-based therapy) can not preclude the occurrence of arrhythmia events and/or provide complete protection. With growing understanding of the genetic background and molecular mechanisms of inherited cardiac arrhythmias, advancing insight of stem cell technology, and development of vectors and delivery strategies, gene therapy and stem cell therapy may be promising approaches for treatment of inherited cardiac arrhythmias. Recent years have witnessed impressive progress in the basic science aspects and there is a clear and urgent need to be translated into the clinical management of arrhythmic events. In this review, we present a succinct overview of gene and cell therapy strategies, and summarize the current status of gene and cell therapy. Finally, we discuss future directions for implementation of gene and cell therapy in the therapy of inherited cardiac arrhythmias.
Powdery mildew is a devastating disease that affects wheat yield and quality. Wheat wild relatives represent valuable sources of disease resistance genes. Cloning and characterization of these genes will facilitate their incorporation into wheat breeding programs. Here, we report the cloning of Pm57, a wheat powdery mildew resistance gene from Aegilops searsii. It encodes a tandem kinase protein with putative kinase-pseudokinase domains followed by a von Willebrand factor A domain (WTK-vWA), being ortholog of Lr9 that mediates wheat leaf rust resistance. The resistance function of Pm57 is validated via independent mutants, gene silencing, and transgenic assays. Stable Pm57 transgenic wheat lines and introgression lines exhibit high levels of all-stage resistance to diverse isolates of the Bgt fungus, and no negative impacts on agronomic parameters are observed in our experimental set-up. Our findings highlight the emerging role of kinase fusion proteins in plant disease resistance and provide a valuable gene for wheat breeding.
The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections.
Somatostatin analogues of formula (I) and their acid addition salts are new. (where R is H, an aminoacid or a dipeptide e.g. Ala-Gly; X1 is (L) trp or (I) Trp; X2 is (L) Thr, (D) Phe or a bond; X3 is (L) Ser or a bond; Cys is (L) Cys or (D) Cys and AzaA is a non-natural, alpha aminoacid gp. in which the metric C atom of alanine is replaced by N, i.e. NH = N(CH3)-CO-). PHE is Phe. This is not in formula as printed but covers most claimed cpds. (I) regulate the secretion of insulin, glucagon and growth. hormone and may be used to regulate glycemic levels in insulin dependent and non-insuling dependent diabetes and to control acromegalia. Unlike somatostatin, (I) have little effect on gastric secretion and are resistant to proteolysis (due to presence of -NH-NCCH3)-CO and the D-aminoacids) by resistant bacterial strains. The activity profile of the cpds. differs from that of somatostatin and each other and suitable cpds. can be selected to give the required activity. (I) are administered as 1-5% solns. by intravenous, intramuscular or sub-cutaneous injection in doses of 0.1-10 mg.
Dentures and dental instruments are cleaned by treating them with an acid cleaning agent containing thio-urea or a derivative thereof. The thio-urea or derivative causes the dissolution of sulphur compounds in the usual tartar film on the dentures &c., the acid present dissolving the remainder of the film.  The articles may be dipped in a solution of the agent or the agent may be applied thereto in the form of a solution, a viscous mass, a powder, or a paste.  The cleaning agent specified comprises an aqueous solution of tartaric acid.  The derivatives of thiourea specified comprise allyl and acetyl thiourea.ALSO:Dental instruments are cleaned by treating them with an acid cleaning agent containing thio-urea or a derivative thereof.  The articles may be dipped in a solution of the agent or the agent may be applied thereto in the form of a solution, a viscous mass, a powder, or a paste.  The cleaning agent specified comprises an aqueous solution of tartaric acid.  The derivatives of thiourea specified comprise allyl and acetyl thiourea.
All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
The present invention relates to a method of treating a subject, in particular a human, suffering from non-small cell lung cancer. Said method comprises a step of administering a bufadienolide to the subject. The present invention further provides a method of inhibiting the 5 proliferation and inducing the cell death of non-small cell lung cancer cells, a method of inhibiting the Epidermal growth factor receptor (EGFR) kinase activity in non-small cell lung cancer cells harboring an abnormality in the EGFR gene and a method of inhibiting Na*/K* ATPase in non-small cell lung cancer cells comprising contacting said cells with a bufadienolide. 0 The inventors in particular unexpectedly found that Proscillaridin A as bufadienolide that has a structure of Formula (Ill) has advantageously high cytotoxicity against EGFR-dependent non-small cell lung cancer at nano-molar levels while having low toxicity to normal lung cells representing the first report of Proscillaridin A in non-small cell lung cancer as specific subtype of lung cancer and in EGFR-dependent non-small cell lung cancer, either. * o4 *0 -CC - D r- *. C)C o* 0 -- 4 oo* oo *l * LL uLE -* * . W- CD i iN - (%) 4rqUtA }JXD JO aEJtIDd
Cefaclor is well absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three fourths to 1 hour later. Following administration of 250 mg, 500 mg, and 1 g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL, respectively, were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations following the 250 mg, 500 mg and 1 g doses were approximately 600, 900 and 1,900 mcg/mL, respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%.
Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
Background and Objectives: Prolonged bed rest after the resection of spinal intradural tumors is postulated to mitigate the development of cerebrospinal fluid leaks (CSFLs), which is one of the feared postoperative complications. Nonetheless, the empirical evidence supporting this conjecture remains limited and requires further investigation. The goal of the study was to investigate whether prolonged bed rest lowers the risk of CSFL after the resection of spinal intradural tumors. The primary outcome was the rate of CSFL in each cohort. Materials and Methods: To validate this hypothesis, we conducted a comparative effectiveness research (CER) study at two distinct academic neurosurgical centers, wherein diverse postoperative treatment protocols were employed. Specifically, one center adopted a prolonged bed rest regimen lasting for three days, while the other implemented early postoperative mobilization. For statistical analysis, case-control matching was performed. Results: Out of an overall 451 cases, we matched 101 patients from each center. We analyzed clinical records and images from each case. In the bed rest center, two patients developed a CSFL (n = 2, 1.98%) compared to four patients (n = 4, 3.96%) in the early mobilization center (p = 0.683). Accordingly, CSFL development was not associated with early mobilization (OR 2.041, 95% CI 0.365-11.403; p = 0.416). Univariate and multivariate analysis identified expansion duraplasty as an independent risk factor for CSFL (OR 60.33, 95% CI: 0.015-0.447; p < 0.001). Conclusions: In this CER, we demonstrate that early mobilization following the resection of spinal intradural tumors does not confer an increased risk of the development of CSFL.
BACKGROUND: Reverse total shoulder arthroplasty (RTSA) is commonly performed to reduce pain and restore shoulder function in patients with severe shoulder conditions. While most patients experience significant pain relief and functional improvement following surgery, a subset of patients continue to report persistent pain even two years postoperatively. The aim of this study was to identify both modifiable and non-modifiable preoperative factors that contribute to the risk of persistent postsurgical pain after RTSA. By understanding these factors, clinicians can better anticipate which patients are at higher risk and develop tailored preoperative and postoperative pain management strategies to improve overall outcomes.
METHODS: In this retrospective cohort study, 703 patients with complete data undergoing primary RTSA performed between 2011 and 2022 were analyzed. Persistent postsurgical pain was defined as a pain score ≥ 3 on a numeric rating scale. Multivariable regression models were used to identify patient-related and disease-related predictors of persistent postsurgical pain.
RESULTS: The cohort comprised 445 women (63%) and 258 men (37%) with a mean age of 74 ± 8 years at the time of surgery. Persistent postsurgical pain was reported by 18% of patients. Preoperative pain scores averaged 6.0 ± 2.5 on the NRS scale, which decreased to 1.2 ± 1.8 postoperatively. Key predictors included higher preoperative pain levels (β = 0.10, p < 0.001), worse preoperative QuickDASH scores (β = 0.09, p = 0.002), mild symptoms of anxiety or depression (β = 0.52, p = 0.001), prior contralateral TSA surgery (β = 0.34, p = 0.018) and greater number of previous ipsilateral shoulder surgeries (β = 0.44, p < 0.001). In contrast, patients with rheumatoid arthritis (β = - 0.85, p < 0.001) or primary osteoarthritis (β = - 0.82, p < 0.001) experienced lower pain levels.
CONCLUSION: Our study offers important insights into the predictors of persistent postsurgical pain two years after RTSA. Key factors, including higher preoperative pain scores, poor mental health, elevated QuickDASH scores, prior contralateral TSA surgery and a history of prior ipsilateral shoulder surgeries, were identified as significant risk indicators for persistent postsurgical pain.
Patients are randomized (2:1) to either the intensive or standard treatment (control). Those who get randomized into the intensive group go to a family-based weight management program, including exercise, nutrition, behavior modification, and parenting classes. The intensive group is further randomized into a diet or non-dieting class to compare the outcomes of two different nutrition intervention methods. These classes meet twice per week (exercise twice per week and nutrition/behavior modification once per week)for first six months and then only twice per month during last six months. An exercise physiologist supervises the exercise component, which involves 45 minutes of aerobic activity (targeted at 65 to 80 percent of the subject's estimated maximum heart rate. A registered dietitian facilitates the nutrition and behavior component. A social worker facilitates parent classes when the children have a behavior modification topic in their class (parents only attend nutrition sessions). Those who get randomized into the control group go to clinic visits every 6 months. Intervention subjects go to clinic, as well, every 6 months to obtain the same measurements as the controls (weight, BMI, % fat, fasting insulin, fasting glucose, lipids, blood pressure).
Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants as well as multiple KIT exon 11, 11/17 and 17 mutants with half maximal inhibitory concentrations (IC50s) less than 25 nM in biochemical assays. Certain mutations in PDGFRA and KIT can result in the autophosphorylation and constitutive activation of these receptors which can contribute to tumor and mast cell proliferation. Other potential targets for avapritinib include wild type KIT, PDGFRB, and CSFR1.

In cellular assays, avapritinib inhibited the autophosphorylation of KIT D816V with an IC50 of 4 nM, approximately 48-fold lower concentration than wild-type KIT. In cellular assays, avapritinib inhibited the proliferation in KIT mutant cell lines, including a murine mastocytoma cell line and a human mast cell leukemia cell line. Avapritinib also showed growth inhibitory activity in a xenograft model of murine mastocytoma with KIT exon 17 mutation.

Avapritinib inhibited the autophosphorylation of PDGFRA D842V, a mutation associated with resistance to approved kinase inhibitors, with an IC50 of 30 nM. Avapritinib also had anti-tumor activity in mice implanted with an imatinib-resistant patient-derived xenograft model of human GIST with activating KIT exon 11/17 mutations.